Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
55.3 EUR | +0.18% | +1.10% | -1.95% |
Jul. 01 | US FDA Approves Formycon's Biosimilar to Treat Serious Retinal Diseases | MT |
Jun. 18 | Borse Frankfurt-News: Many winners and many losers (second-line stocks) | DP |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.95% | 1.06B | |
+23.50% | 45.01B | |
+47.19% | 40.96B | |
-5.16% | 38.62B | |
+36.37% | 32.6B | |
-7.79% | 27.49B | |
+18.06% | 27.17B | |
+47.29% | 14.61B | |
+41.91% | 12.95B | |
-1.02% | 11.36B |
- Stock Market
- Equities
- FYB Stock
- News Formycon AG
- US FDA Accepts Formycon's Biologics License Application for Eylea Biosimilar